Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro - Wikidata - awgldk - TriplyDB

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

http://www.wikidata.org/entity/Q33853775

about

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals The aftermath of the Merck's HIV vaccine trial Structural definition of a conserved neutralization epitope on HIV-1 gp120 Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 Antibody responses to envelope glycoproteins in HIV-1 infection The Antibody Response against HIV-1 A global approach to HIV-1 vaccine development HIV broadly neutralizing antibody targets Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV Sang Froid in a time of trouble: is a vaccine against HIV possible?Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates Wanted, dead or alive: New viral vaccines Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120 A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing Epitope Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor New concepts in HIV-1 vaccine development Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization Antibodies for HIV prevention in young women Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Broad neutralization coverage of HIV by multiple highly potent antibodies Rapid evolution of the neutralizing antibody response to HIV type 1 infection Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies Survivors Remorse: antibody-mediated protection against HIV-1.Passive immunization against HIV/AIDS by antibody gene transfer.

P2860

Q24561905-EC908ABF-B8DA-4514-A821-0D748B157BD8 Q24635002-A0A33721-8336-4290-BB28-E2240CD84B70 Q24654458-581F5306-4781-422B-AF1C-FBD331D5E191 Q24655948-3836F99C-7D5D-4F5A-9BC4-B6D8076D5DA9 Q26765043-8CD8E3BA-D3F0-45CA-AED6-143857F8A056 Q26782237-83104726-541A-41C6-B319-94577D97C3DC Q26991572-D6BF61ED-A5F3-40BA-B5C4-FFCB27966AB1 Q27000889-DEDFE196-7B4F-4534-8747-ACA24F76672C Q27024614-2BEF04B5-714D-45C7-9FC3-F17D31251FEC Q27026662-86160C66-E189-4D77-A8FD-8DA7A390F802 Q27313556-C351CE2A-D915-4EDA-9122-089E94E1A5CB Q27322437-3F5628FE-C9CF-48F5-83C6-5C5732AA66AE Q27324184-1587B47C-8C9F-4E0A-8A48-50D8B7A27D1D Q27342615-9FB9EB55-2C39-4B78-A8EE-E5A2A05BDE12 Q27349203-A4A90D21-7166-4B17-9E27-E86E214AD696 Q27487961-7B13787D-23C8-4879-939E-3DF42631023C Q27489000-958C2AFD-8987-4A96-8098-B50EEE73EBCD Q27489979-F3CA75EF-47D9-4B58-8F3A-8934C3037E34 Q27640572-4AC310DA-0891-478D-9A7A-E54F9A635DBF Q27649541-CD351662-3936-426F-926A-21652BFB085B Q27655865-4E642038-A8BE-41C7-829B-0953D5DEB413 Q27662155-4E3735F1-F956-409F-BD46-AC5598DD3B2C Q27674878-B78C1811-A3C5-4DF3-AAC0-9EC2BBAD7AAE Q27675260-F5121B6D-A67F-4324-B409-326AE51574F7 Q27675486-32F8C48F-3606-4F5D-B6CF-C639B8B23D2B Q27684529-C4A16411-3F58-43CA-9D73-B7E8E39B0081 Q28067027-683E7D4F-53B6-4355-AB59-806FEB9699A0 Q28068018-708ADECA-F139-414D-BD41-0999CB6E86BA Q28082033-E3BD2C8C-FB1D-4414-8A46-2A3135B5A475 Q28217208-C4ED52B2-C3C6-46C4-A701-213C236A281D Q28469023-2D42FE73-52C4-420D-856E-0B27BBEF1B25 Q28535583-A891FA3A-20B1-469F-9DF9-E76495A83E34 Q28545185-46CE2A49-B252-4AAE-B3A2-C69725B1EDC2 Q28752503-16E002CD-8D4F-427F-BC83-799C257CDDDE Q29547347-C8608653-2543-4980-B0F9-D989818F0E3E Q29615361-F7133710-A413-4B27-B6F4-5060FDD49EFE Q29618603-FCE74A38-64BE-423A-88C6-28BAB403DD3B Q29619015-BA48CDDA-3C6F-49AE-B4A8-D797D91FE9B1 Q30238730-61207430-1F51-4229-997C-31DDE1EC7A51 Q30358434-17615B3B-85F0-4454-8056-C3DBCAA1E49D

P2860

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

http://www.wikidata.org/entity/Q33853775

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Antibody protects macaques aga ...... mplete neutralization in vitro

@ast

Antibody protects macaques aga ...... mplete neutralization in vitro

@en

type

label

Antibody protects macaques aga ...... mplete neutralization in vitro

@ast

Antibody protects macaques aga ...... mplete neutralization in vitro

@en

prefLabel

Antibody protects macaques aga ...... mplete neutralization in vitro

@ast

Antibody protects macaques aga ...... mplete neutralization in vitro

@en

P1433

Q33853775-5B8FC004-F0B7-4F69-8FEB-B514F0EA6377

P1476

Q33853775-F7026009-E30B-424F-A558-B824B4087E39

P2093

Q33853775-4EB9224B-BBD2-4711-B37F-3238228AB1AF

Q33853775-6054B063-08DE-41C5-810C-2EFF480ADFCA

Q33853775-6456363D-290C-44E3-AB59-C2CF3BB74594

Q33853775-7715AFE1-660E-4561-BBDD-3ACB6D172849

Q33853775-9BD7865B-73D4-44F0-9521-8402F35FCFC7

Q33853775-9C3F71BD-4EC7-4350-A083-EE9DDE926F60

Q33853775-A8C06CF5-A239-41DA-9698-7BCDAF36EC08

Q33853775-E6D614B7-2A6C-498A-9AFE-1AAD4F285041

P2860

Q33853775-0270D170-4F29-4796-9B95-5CBD7BB75AF0

Q33853775-0F5653E2-8485-46AB-8182-311E979ECBDC

Q33853775-1078D7D3-0DDB-413C-BB05-E430E5EA6FC2

Q33853775-165B6FCF-4DC9-45E9-95DA-64DD3407B2EE

Q33853775-1CAB35D8-70FD-48C1-B2D9-4AE69236ED79

Q33853775-21C856B9-FA92-4BFC-A646-34A174E57FE6

Q33853775-261E3009-1650-4F02-B36B-6B55018B1496

Q33853775-37532F3A-BF6D-432C-BC56-03F335365F4D

Q33853775-3A2C0397-61F3-4042-BF7D-7B0410EF9111

Q33853775-3ADF5E68-1173-4CB4-9818-F1A66A1D0DF9

P304

Q33853775-92E80FBF-37F1-4B47-94C3-202797B54AFC

P31

Q33853775-EEF655EB-F22B-42BC-9F37-6A80BBCE9CCF

P356

Q33853775-B2537042-2496-482D-8160-7494A1957296

P433

Q33853775-44B11145-63E0-4EEB-ACF2-6533FF805F95

P478

Q33853775-00122543-7D6D-43EA-B5A9-FB7D3921277B

P577

Q33853775-20A2E686-8780-4605-B0F0-35EC1C3D19E4

P698

Q33853775-B21EDF24-2336-4B2E-B53A-FFC15C689F74

P921

Q33853775-04E3B3EF-E295-44C0-A4F6-BA18B62A0CED

P932

Q33853775-4AE10901-C5F1-436C-B39E-37A547F615F6

P356

JVI.75.17.8340-8347.2001

P1433

Journal of Virology

P1476

Antibody protects macaques aga ...... mplete neutralization in vitro

@en

P2093

A J Hessell

http://www.w3.org/2001/XMLSchema#string

A Luckay

http://www.w3.org/2001/XMLSchema#string

C Cheng-Mayer

http://www.w3.org/2001/XMLSchema#string

D R Burton

http://www.w3.org/2001/XMLSchema#string

J Harouse

http://www.w3.org/2001/XMLSchema#string

J P Moore

http://www.w3.org/2001/XMLSchema#string

P A Marx

http://www.w3.org/2001/XMLSchema#string

P W Parren

http://www.w3.org/2001/XMLSchema#string

P2860

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.

Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells.

Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate

P304

8340-8347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.75.17.8340-8347.2001

http://www.w3.org/2001/XMLSchema#string

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11483779

http://www.w3.org/2001/XMLSchema#string

P921

P932

115078

http://www.w3.org/2001/XMLSchema#string